ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / AMRN / options
ABEO (23) CAMP (26) IFRX (54) GLSI (31) ⌘ Pro Terminal β†’

Amarin Corporation plc (AMRN) Options Positioning, Max Pain & Unusual Sweeps

$12.13 +0.17% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.11

Amarin Corporation plc (AMRN) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $249.9M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AMRN Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is AMRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Amarin Corporation plc (NASDAQ: AMRN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $12.13 (+0.17% 1D, market cap $249.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, AMRN ranks #716 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does AMRN compare to ABEO and CAMP in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMRN carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -12.2%. By comparison, ABEO (Abeona Therapeutics Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $248.8M) and CAMP (CAMP4 Therapeutics Corporation) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $248.5M). Among the 5-stock peer group, AMRN leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AMRN?
β–Ό

Per AMRN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000897448), Amarin Corporation plc generated $213.6M in revenue (-6.5% YoY), -$38.8M in net income, and $6.7M in free cash flow against $670.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $12.11 (-0.16%)🧬 Disciplined Float (+0.16% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 3.1% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (32/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510032
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk E
Cash (8)Whales (5)SEC (6)Macro (6)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-11.7% Base Target
$18 Bull$11 Base$8 Bear
πŸ“¬ FREE AMRN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for AMRN)Realized 20D OHLCV Swing Band: Β±7.2%
Deterministic 5-Pillar Attribution (32/100 Composite)
πŸ” WHY AMRN SCORES 32/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+8/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 3.1% FCF Margin ($6.7M FCF) & 56.6% Gross Margin

β–² #2 Bullish Driver: Insider Conviction & Share Dilution+7/20 pts (22% of score)

SEC Form 4 / 13F Thermometer: 35% Net Buy β€’ Disciplined Float (+0.16% YoY Shares)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
24
Grade E$11.58-0.9% Next Q
Q2 (-2Q)
27
Grade E$11.48+4.1% Next Q
Q3 (-1Q)
29
Grade E$11.95+1.5% Next Q
Current
32
Grade E$12.13-9.2% Hist 90D Ξ±
Trajectory: E (24) β†’ E (32)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a AMRN Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While AMRN currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.91) and Max Pain ($12.74) forces dealer call-delta covering toward $18.18.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMRNβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œAMRN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±7.2%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (AMRN)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for AMRN.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AMRN)

  • βœ“Walkthrough of AMRN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
AMRN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.82%β–Ό DESCENDING CHANNEL
2026-11-03O $12.73H $12.73L $12.11C $12.13VOL 101.3K
RES: $13.04SUP: $10.80SMA50: $12.91SMA200: $14.29
$17.67$15.93$14.19$12.45$10.71RES $13.04SUP $10.80$12.132026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMRN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ AMRN Butterfly Map β†’ + Track AMRN β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -6.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AMRN today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for AMRN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AMRN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMRN)

Health Care Rank #716 of 1015 βš”οΈ ABEO vs AMRN Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (AMRN vs. ABEO, CAMP, IFRX, GLSI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Amarin Corporation plc (AMRN) ranks #716 by composite RQD confidence (32/100, grade E) and #540 by equity capitalization ($249.9M). Within this direct 5-issuer industry benchmark cohort, AMRN leads on earnings valuation at N/A trailing P/E, while AMRN leads on capital efficiency and profitability with -12.2% ROIC and 56.6% gross margin. IFRX currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with AMRN at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AMRN ACTIVE
Amarin Corporation plc
E 32/100 β€” 56.6% -12.2% +0.17% $249.9M Benchmark Subject
ABEO
Abeona Therapeutics Inc.
E 23/100 β€” 73.7% -35.0% -2.30% $248.8M /abeo-vs-amrn β†’
CAMP
CAMP4 Therapeutics Corporation
E 26/100 β€” β€” -35.0% -4.67% $248.5M /camp-vs-amrn β†’
IFRX
InflaRx N.V.
D+ 54/100 β€” β€” β€” +6.33% $244.6M /ifrx-vs-amrn β†’
GLSI
Greenwich LifeSciences Inc.
E 31/100 β€” β€” -35.0% -5.46% $255.5M /glsi-vs-amrn β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0000897448 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amarin Corporation plc (AMRN) reported GAAP revenue of $213.6M (-6.5% vs. FY2024 revenue of $228.6M , and -30.4% cumulative change since FY2023) , GAAP net income of -$38.8M, operating cash flow of $6.7M, and free cash flow of $6.7M (+121.7% YoY). On the balance sheet, AMRN closed FY2025 with $670.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $213.6M -$38.8M $6.7M $6.7M $670.8M β€”
FY2024 (FY) 2024-12-31 $228.6M -$87.0M -$31.0M -$31.0M $685.3M β€”
FY2023 (FY) 2023-12-31 $306.9M -$55.0M $6.9M $6.9M β€” β€”

3. AMRN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Amarin Corporation plc (NASDAQ: AMRN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $12.13 (+0.17% 1D, market cap $249.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, AMRN ranks #716 in composite RQD confidence.

How does AMRN compare to ABEO and CAMP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMRN carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -12.2%. By comparison, ABEO (Abeona Therapeutics Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $248.8M) and CAMP (CAMP4 Therapeutics Corporation) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $248.5M). Among the 5-stock peer group, AMRN leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AMRN?

Per AMRN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000897448), Amarin Corporation plc generated $213.6M in revenue (-6.5% YoY), -$38.8M in net income, and $6.7M in free cash flow against $670.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AMRN trading relative to its 50-day, 200-day, and 52-week technical levels?

AMRN last traded at $12.13 (+0.17% on volume of 100,144 shares), positioning the stock -6.04% below its 50-day simple moving average ($12.91) and -15.12% below its 200-day simple moving average ($14.29). Across its 52-week range of $11.25 to $17.31, AMRN sits at the 14.5% percentile with a 14-day RSI of 47.1 (NEUTRAL RANGE) and an implied next-earnings move of Β±7.2% ($11.26 to $13.00).

Direct Sub-Reports: AMRN RQD Cockpit AMRN 12M Forecast AMRN Earnings & Move AMRN Dividends & DRIP AMRN Insiders & 13F AMRN Whale Options AMRN Profit Sankey AMRN News & Why
ROARABLE RATING BRIEF β€’ RQD 32/100 (E) βœ“ SEC XBRL & RQD VERIFIED

AMRN β€” Amarin Corporation plc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Amarin Corporation plc (AMRN) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $12.13 (+0.17% 1D, market capitalization $249.9M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -12.2%, gross margin of 56.6%, operating margin of -23.5%, and free cash flow yield of 2.56%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (6/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 6/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Amarin Corporation plc is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations..3B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Amarin Corporation plc (AMRN) reported $213.6M in annual revenue (up from $228.6M in FY2024, -6.5% YoY) and -$38.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($306.9M revenue, -$55.0M net income) through FY2025, AMRN scaled operating cash flow to $6.7M and free cash flow to $6.7M, backed by $670.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 2.56% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $11.25 – $17.31 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -23.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), AMRN carries a macro regime beta of 1.00 and gross margin of 56.6%.

  • Key Question #1: Can AMRN sustain or expand its -23.5% operating margin and -12.2% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $213.6M and free cash flow of $6.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is AMRN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AMRN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Amarin Corporation plc (AMRN) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to AMRN Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AMRN Bull vs. Bear Conversation Board β€” What's Your Call at $12.13?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AMRN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AMRN:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER β€’ FCF Compounder Hunter πŸ‚ BULLISH 🎯 Target: $15.02 (+24.0%)
πŸ“Œ Pinned Debate

Per the news feed, Amarin reportedly returned to quarterly profit as cost reductions offset a 20% revenue decline, with Q3 earnings bea

Here is why I am bullish on AMRN here at $12.11: Per the news feed, Amarin reportedly returned to quarterly profit as cost reductions offset a 20% revenue decline, with Q3 earnings beating estimates.. Compare AMRN's -23.5% operating margin and -12.2% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $11.50 are getting bought.

SectorRotator πŸ‚ BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (56.6%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER β€’ Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $9.81 (-19.0%)
Spot @ $12.11

Per the Roarable RQD rating, an Altman Z-Score of 0.2 and ROIC of -12.2% signal balance-sheet fragility and negative returns on capital

Careful chasing AMRN at $12.11. Per the Roarable RQD rating, an Altman Z-Score of 0.2 and ROIC of -12.2% signal balance-sheet fragility and negative returns on capital.. Gross margin is 56.6%, but operating margin is -23.5%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $9.81 on multiple compression.

LIVE TAPE